Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

Cost-effectiveness analysis of pembrolizumab plus chemotherapy for previously untreated metastatic non-small cell lung cancer in the USA

Objectives Evaluating the cost-effectiveness of pembrolizumab plus standard chemotherapy in the first-line setting for patients with metastatic non-small cell lung cancer (NSCLC) from the US payer perspective.Design A Markov model was constructed to analyse the cost-effectiveness of pembrolizumab pl...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaohui Zeng, Xiaomin Wan, Liubao Peng, Ye Peng, Fang Ma, Qiao Liu, Chongqing Tan
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2019-12-01
Series:	BMJ Open
Online Access:	https://bmjopen.bmj.com/content/9/12/e031019.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
by: Xiaohui Zeng, et al.
Published: (2020-11-01)

Enfortumab vedotin plus pembrolizumab for previously untreated locally advanced or metastatic urothelial carcinoma: a cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2025-01-01)

Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in the Chinese healthcare system
by: Wenwang Lang, et al.
Published: (2025-01-01)

Outcomes of Pembrolizumab plus chemotherapy for patients with metastatic non-squamous NSCLC: Real-world evidence
by: Irina Surovtsova, et al.
Published: (2025-12-01)

Impact of corticosteroids on the efficacy of first-line pembrolizumab plus chemotherapy in patients with advanced non-small-cell lung cancer
by: Amytis Roboubi, et al.
Published: (2025-02-01)

Alternating modified CAPOX/CAPIRI plus bevacizumab in untreated unresectable metastatic colorectal cancer: a phase 2 trial
by: Sheng Li, et al.
Published: (2024-12-01)

Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
by: Ella Xiaoyan Du, et al.
Published: (2024-08-01)

Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study
by: Yu Lin, et al.
Published: (2024-11-01)

Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre
by: Maria João Santos, et al.
Published: (2025-02-01)

Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases
by: Daisuke Matsumoto, et al.
Published: (2025-01-01)

Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain
by: Eva Tirado Mercier, et al.
Published: (2018-01-01)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China.
by: Chaoneng He, et al.
Published: (2024-01-01)

Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China
by: Caicong You, et al.
Published: (2024-12-01)

Editorial Comment on “Efficacy of pembrolizumab plus lenvatinib as first‐line treatment for metastatic renal cell carcinoma with multiple brain metastases”
by: Manabu Kato
Published: (2025-01-01)

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma
by: Christian Mueller, et al.
Published: (2020-10-01)

Impact of Cachexia and First‐Line Systemic Therapy for Previously Untreated Advanced Non‐Small Cell Lung Cancer: NEJ050A
by: Keita Miura, et al.
Published: (2024-12-01)

Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report
by: Chul Kim, et al.
Published: (2021-07-01)

Cost‐effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR‐mutated advanced non‐small cell lung cancer
by: Wentao Tian, et al.
Published: (2024-08-01)

Comparison of lenvatinib plus pembrolizumab versus first-line systemic chemotherapy for advanced intrahepatic cholangiocarcinoma: a real-world retrospective study
by: Zhenyun Yang, et al.
Published: (2024-11-01)

Pembrolizumab (MK-3475) plus platinum and gemcitabine as first-line treatment of recurrent/metastatic head and neck squamous cell carcinoma (PIPER): a phase 2, multicentre, single-arm protocol study in Malaysia
by: Gwo Fuang Ho, et al.
Published: (2024-12-01)

A phase 3 study of the efficacy, safety, and pharmacokinetics profile of subcutaneous vs intravenous nivolumab + relatlimab fixed-dose combination in previously untreated metastatic or unresectable melanoma (RELATIVITY-127)
by: G.V. Long, et al.
Published: (2024-01-01)

Tumor Lysis Syndrome Due to Pembrolizumab Use in Metastatic Nasopharyngeal Carcinoma
by: Aykut Turhan, et al.
Published: (2024-01-01)

Utility of pembrolizumab for metastatic castrate resistant prostate cancer with MMR deficiency
by: Brian F. Dinerman, et al.
Published: (2024-11-01)

Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis
by: Hongbo He, et al.
Published: (2024-12-01)

Immunotherapy after progression to immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition
by: G. Lyrarakis, et al.
Published: (2024-01-01)

Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial
by: Chad Tang, et al.
Published: (2020-10-01)

Comment on ‘Impact of Cachexia and First‐Line Systemic Therapy for Previously Untreated Advanced Non‐Small Cell Lung Cancer: NEJ050A’ by Miura et al.
by: Wei‐Zhen Tang, et al.
Published: (2024-12-01)

Cryoablation plus chemotherapy regimen enhance anti-tumor immune response in a mouse model of Lewis lung cancer
by: Hua Duan, et al.
Published: (2024-12-01)

First-line benmelstobart plus anlotinib and chemotherapy in advanced or metastatic/recurrent esophageal squamous cell carcinoma: a multi-center phase 2 study
by: Ning Li, et al.
Published: (2024-11-01)

Phase I study of pembrolizumab in combination with ibrutinib for the treatment of unresectable or metastatic melanoma
by: Yuan Yao, et al.
Published: (2025-02-01)

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China
by: Wenwang Lang, et al.
Published: (2024-11-01)

Trastuzumab plus chemotherapy versus chemotherapy alone in HER2-positive gastric cancer treatment in Iran: a cost-effectiveness analysis
by: Sara Kaveh, et al.
Published: (2024-11-01)

Chemotherapy for Metastatic Gastric Cancer
by: Sung Eun Kim, et al.
Published: (2025-01-01)

Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer
by: Caicun Zhou, et al.
Published: (2020-10-01)

The Use of Natural Health Products Especially Papaya Leaf Extract and Dandelion Root Extract in Previously Untreated Chronic Myelomonocytic Leukemia
by: Leena T. Rahmat, et al.
Published: (2018-01-01)

Toripalimab plus chemotherapy for metastatic muscle-invasive bladder cancer with a high tumor proportion score: a case report
by: Wei Ning, et al.
Published: (2024-12-01)

Cost-effectiveness of brentuximab vedotin plus chemotherapy as frontline treatment of stage IV Hodgkin lymphoma in Italy
by: Chiara Bini, et al.
Published: (2024-12-01)

The Hidden Cost of Untreated Paragangliomas of the Head and Neck: Systemic Reactive (AA) Amyloidosis
by: Erkan Dervisoglu, et al.
Published: (2015-01-01)

A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer
by: Yinghui Xu, et al.
Published: (2023-02-01)